Types of Mesothelioma By Location & Cell Type
The types of mesothelioma are based on the location where the cancer develops and its cell type. For example, when it forms in the pleural lining around the lungs, the cancer is called pleural mesothelioma.
Each mesothelioma type can lead to different symptoms. Treatment is tailored by cell variety. The prognosis varies by mesothelioma tumor location, too.
Primary types of mesothelioma by location and cell type:
- Pleural mesothelioma (lungs)
- Peritoneal mesothelioma (abdomen)
- Pericardial mesothelioma (heart)
- Testicular mesothelioma (testes)
- Epithelioid mesothelioma (epithelioid cells)
- Sarcomatoid mesothelioma (sarcomatoid cells)
- Biphasic mesothelioma (epithelioid and sarcomatoid cells)
- Other rare cell types
Get a Free Mesothelioma Guide
Free information, books, wristbands and more for patients and caregivers.Get Your Free Guide
Pleural is the most common mesothelioma. Approximately 70% to 75% of cases occur in the pleura. More research has been conducted on this mesothelioma tumor than any of the others.
Most patients qualify for chemotherapy, radiation therapy. Some may qualify for immunotherapy. These therapies can add months or years to life expectancy.
Characteristics of Pleural Mesothelioma
- Location: Pleural lining (chest)
- Symptoms: Shortness of breath, chest pain, weight loss, fever and fatigue
- Prognosis: With treatment, 3+ years at stage 1 versus 12 months at stage 4
Peritoneal disease accounts for 10% to 20% of mesothelioma cases. There is less research available on peritoneal compared to pleural; however, the prognosis for this tumor type is better.
According to research, around half of peritoneal mesothelioma patients who have surgery and heated chemotherapy (HIPEC) live five or more years after diagnosis.
Characteristics of Peritoneal Mesothelioma
- Location: Lining of the abdomen (peritoneum)
- Symptoms: Abdominal pain and swelling, bloating, loss of appetite and bowel changes
- Prognosis: 52% live at least five years after surgery with HIPEC
The pericardial tumor type is extremely rare. Around 200 cases are reported in medical literature. With surgery, some patients live for years beyond the average six-month life expectancy.
Characteristics of Pericardial Mesothelioma
- Location: Lining of heart (pericardium)
- Symptoms: Irregular heartbeat, chest pain, difficulty breathing and cough
- Prognosis: Typically ranges from six weeks to 15 months
Testicular mesothelioma develops in the lining of the testes. This form of mesothelioma is the most rare. Less than 100 cases are reported in the medical literature.
Treatment options include surgery and chemotherapy, which can help people live more than two years after diagnosis, on average.
Characteristics of Testicular Mesothelioma
- Location: Forms in the tunica vaginalis, which is the lining covering the testes
- Symptoms: Scrotal swelling, painless testicular lumps
- Prognosis: 2 years
Three Types of Mesothelioma Cells
The three mesothelioma cell varieties are epithelial, sarcomatoid and biphasic. Biphasic is a mix of the first two cell types.
Mesothelioma doctors can tell the difference between cells based on how they look under a microscope.
Different mesothelioma tumors respond differently to treatment. Epithelial or epithelioid cells respond the best, and sarcomatoid cells are more resistant to treatment.
Cancer doctors take these differences into account when planning your mesothelioma treatment. Incidence of these cell types varies by cancer location.
Epithelial Cell Mesothelioma
Epithelioid mesothelioma makes up approximately 70% to 75% of all cases of asbestos-related mesothelioma cancers.
Epithelioid cell has the best prognosis. It tends to be less aggressive and doesn’t spread as quickly as sarcomatoid and biphasic cell disease.
About 50% of pleural disease is epithelioid. Around 75% of peritoneal tumors are made up of epithelioid cells.
Sarcomatoid Cell Mesothelioma
Sarcomatoid mesothelioma is the least common mesothelioma cell category. It is the most aggressive and difficult to treat. It accounts for around 10% to 20% of all mesothelioma diagnoses.
You may hear sarcomatoid mesothelioma referred to as sarcomatous, spindle or diffuse malignant fibrous mesothelioma.
About 20% of pleural tumors are sarcomatoid, while only 1% of peritoneal mesothelioma are sarcomatous.
Biphasic mesothelioma refers to tumors that contain epithelial and sarcomatoid cells. Life expectancy after diagnosis with biphasic mesothelioma depends upon which cell predominates in the tumor.
More epithelioid cells generally mean a better prognosis. If the tumor is mostly sarcomatous, it is harder to treat and life expectancy is shorter.
Around 30% of pleural and 25% of peritoneal tumors are biphasic cell.
Prevalence of Pleural Mesothelioma Tumors by Cell Type
Prevalence of Peritoneal Mesothelioma Tumors by Cell Type
Based on the limited number of cases reported in the medical literature, pericardial mesothelioma exhibits roughly equal distribution of the three mesothelioma cell types.
Approximately two-thirds of testicular mesothelioma cases are epithelioid cell. The rest of testicular cases are biphasic. Only one case of purely sarcomatoid cell disease is reported for testicular mesothelioma.
Find Clinical Trials for Mesothelioma Patients
Get free help finding and enrolling in a mesothelioma clinical trial today!Find A Clinical Trial
Rare Mesothelioma Cell Types
There are a handful of rare cell subtypes. They can have slightly different characteristics and can affect prognosis.
For example, patients with sarcomatoid tumors tend to have the shortest survival, but some patients with the lymphohistiocytoid subtype of sarcomatoid cell have survived as long as six years.
- Well-differentiated papillary cells commonly occur in peritoneal mesothelioma. Only a handful of cases have been reported in people with other mesothelioma cancer locations.
- Small cell mesothelioma is another cell type that occurs more commonly in the abdomen.
- A little more than half of the cases of deciduoid mesothelioma occur in the abdomen. Slightly less than half arise in the lung lining.
- Cystic and papillary cells are more common in peritoneal mesothelioma.
- Desmoplastic and lymphohistiocytoid are more common in pleural mesothelioma.
- Adenomatoid cells can occur in both malignant mesothelioma and benign mesothelioma.
- Heterologous cells are found in tumors that may also contain bone, cartilage and soft tissue.
Mesothelioma Treatment for Tumor and Cell Type
Your specific mesothelioma diagnosis will influence your treatment options. Different treatments may be available, depending on the location of your cancer and possibly, the cell type.
Surgical procedures to treat pleural mesothelioma include:
- Extrapleural pneumonectomy
- Simple pneumonectomy
Peritoneal tumors are removed with a peritonectomy. Pericardial tumors are removed with a pericardiectomy. Testicular tumors are removed with an inguinal orchiectomy.
A combination of cisplatin and Alimta (pemetrexed) is the most effective regimen against pleural mesothelioma.
Combinations of gemcitabine, Alimta, mitomycin and carboplatin are most effective against peritoneal mesothelioma.
No particular chemotherapy regimen is consistently effective for pericardial or testicular mesothelioma. The two latter types of mesothelioma are so uncommon that they have not been studied enough to know which treatment is best.
In these rare situations, a mesothelioma expert oncologist can devise the best treatment plan based on their experience and your overall health.
In pleural mesothelioma, radiation therapy is used with and without surgery. Radiation therapy typically isn’t a typical treatment for peritoneal mesothelioma, but it has been used successfully to treat pericardial and testicular mesothelioma.
The goal of palliative therapy is to alleviate pain and other symptoms of the disease. Palliative care can significantly improve quality of life and well-being of mesothelioma patients.
For example, thoracentesis can be employed to drain fluid from around the lungs, and paracentesis is used to remove fluid from the abdomen. These procedures can alleviate pain and pressure and make breathing and eating easier for you.
Selecting the Right Treatment
To find the right treatment for each patient, doctors consider many factors. This includes cancer stage, a patient’s age and overall health and the patients desires and needs going into treatment.
Surgery may be recommended to early-stage patients who are younger and in good health. Chemotherapy, radiation therapy and immunotherapy are available to every patient regardless of stage or age.
17 Cited Article Sources
Harris, E.J.A. et al. (2019, January 16). Diagnosis of asbestos-related lung diseases.
Retrieved from: https://www.tandfonline.com/doi/full/10.1080/17476348.2019.1568875
Regragui, M. and Guebessi, N.B. (2018, November 30). Primary Malignant Deciduoid Mesothelioma: A Challenging Diagnosis.
Retrieved from: https://www.archivesofpathology.org/doi/10.5858/arpa.2017-0461-RS
American Cancer Society. (2018, November 16). Malignant Mesothelioma Stages.
Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/staging.html
Ledda, C. et al. (2018, June 15). Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.
Retrieved from: https://www.mdpi.com/2072-6694/10/6/203
Kindler, H. et al. (2018, May 1). Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
Retrieved from: http://ascopubs.org/doi/pdf/10.1200/JCO.2017.76.6394
Rossini, M. et al. (2018, April 3). New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
Retrieved from: https://www.frontiersin.org/articles/10.3389/fonc.2018.00091/full
Hui, M. et al. (2018, April-June). Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/30604735
Husain, A.N. et al. (2018, January). Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Retrieved from: https://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0124-RA
Marchevsky, A.M. et al. (2017, September). The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Retrieved from: https://www.sciencedirect.com/science/article/pii/S0046817717302678
American Cancer Society. (2017, February 17). How is Malignant Mesothelioma Diagnosed? :
Retrieved from: http://www.cancer.org/Cancer/MalignantMesothelioma/DetailedGuide/malignant-mesothelioma-diagnosed
Alchami, F.S. et al. (2017, February). Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
Retrieved from: https://jcp.bmj.com/content/70/2/179.long
Beebe-Dimmer, J. et al. (2016, October 26). Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival. DOI: 10.2147/CLEP.S105396
Ettinger, D.S. et al (2016, July). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
Retrieved from: http://www.jnccn.org/content/14/7/825.long
Galateau-Salle, F. (2016, 2011). The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Retrieved from: https://www.jto.org/article/S1556-0864(15)00053-2/pdf
Ihemelandu, C. (2015, May). Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome.
- : Retrieved from: https://link.springer.com/article/10.1245%2Fs10434-014-3977-y
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified September 4, 2019